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Novel genetic mutations in genes AGBL5 and TULP1 for presumed unilateral 
retinitis pigmentosa managed with low vision rehabilitation: A case report and 
review 
Abstract 
Background: Retinitis pigmentosa is a group of hereditary retinal diseases characterized by the 
degeneration of rod and cone photoreceptors. It commonly results in night blindness followed by tunnel 
vision and central vision reduction. The classic triad of clinical signs includes pigmented bone spicules, 
waxy disc pallor, and arterial attenuation. Unilateral retinitis pigmentosa is rare and can be supported with 
ancillary testing including genetic and laboratory studies to rule out differential diagnoses. 
Case Report: A 68-year-old Hispanic female was referred to the low vision rehabilitation clinic due to 
progressive vision loss in the left eye (OS) that began 15 years ago. The vision was normal in the right eye 
(OD). Additionally, she suffered from hearing loss in the right ear since age 3. Examination revealed 
abnormal visual acuity, visual field, fundus appearance, optical coherence tomography, and 
electrodiagnostic test results in the OS only. Laboratory studies ruled out various infectious, autoimmune, 
traumatic, and toxic drug etiologies. Genetic testing revealed novel mutations in genes associated with 
retinitis pigmentosa. 
Conclusion: The genetic testing results along with the clinical examination and electrodiagnostic 
evaluation supports the diagnosis of unilateral retinitis pigmentosa. 
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Retinitis pigmentosa (RP) is a genetically inherited group of disorders affecting 1 
in 5,000 people worldwide and 1 in 4,000 in the United States.1 It is commonly 
bilateral with a variety of presentations and progressions. The initial symptom is 
night blindness followed by reduced peripheral visual field. During the later stages 
of the disease, color and central vision become affected.2 Characteristic fundus 
features include pigmented bone spicules, waxy disc pallor, and arterial attenuation. 
Other ocular findings include cystoid macular edema and posterior subcapsular 
cataract. The genetic inheritance pattern of RP varies, and may be autosomal 
dominant, autosomal recessive, X-linked recessive, or sporadic.1 
 
Although there is no cure for retinitis pigmentosa, there are options for supportive 
care.  One example is nutriceutical vitamin supplementation.   Research has shown 
that taking a high dose of vitamin A palmitate (15,000 IU daily), omega-3 rich 
foods, and a lutein supplement may slow the progression of RP.2,3 Additional 
prophylactic measures include protective sunglasses and avoiding smoking, since 
exposure to ultraviolet light and smoking increases oxidative damage and 
accelerates retinal degeneration.3 If sequelae occur, such as cystoid macular edema, 
off-label carbonic anhydrase inhibitors may be considered and have been reported 
to have a response rate of 40 to 50%.4,5 
 
Gene and stem cell therapies are two exciting and rapidly evolving areas of 
research. For those patients with RPE65 mutations, a novel gene therapy, 
Luxturna®, was approved in December of 2017 by the Food and Drug 
Administration (FDA). This was the first FDA approved gene therapy for an 
inherited disease in the United States.2,6,7 Gene and stem cell therapies may slow 
retinal degeneration in RP and may also improve visual function.8 Several clinical 
trials targeting other genetic mutations for RP are currently underway.8,9 
 
RP is a heterogenous group of retinal dystrophies with several sequelae resulting 
from different subtypes described. Reclassification of some of these variants is 
likely as we uncover the molecular pathogenesis and define different presentations 
of the disease. Some clinical differentials of RP include: 
 
- Minor asymmetrically bilateral RP: The common form of RP is bilateral, but  
  the disease progresses faster in one eye compared to the fellow eye. This results  
  in minor asymmetry in RP presentation.10 
- Unilateral RP (URP): The first case of URP was described in 1948 by Dreisler.10  
  Since then, nearly 100 cases of URP have been reported based on the following  
  criteria established by Francois and Verriest:  (i) unilateral ocular RP  
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  presentation, (ii) normal fundus appearance and electroretinogram (ERG)  
  findings in the fellow eye, (iii) exclusion of infectious etiology, and (iv)  
  sufficiently long period of observation (more than 5 years).11,12 These criteria  
  have been supported by later studies, however, there is still controversy  
  concerning the nature of this clinical presentation.13-16 
- Pseudo-RP: There are several etiologies that can mimic RP including infection  
  (i.e., syphilis, toxoplasmosis, rubella, chicken pox, measles, cytomegalovirus),  
  inflammation (i.e.,  uveitis, retinal vasculitis), autoimmunity (i.e.,  cancer- 
  associated retinopathy), trauma (i.e.,  blunt trauma, retinal detachment), or drug  
  toxicity (i.e. chloroquine/hydroxychloroquine, phenothiazines,  
  thioridazine).17,18  
 
From a low vision standpoint, there are options available throughout the course 
of vision loss when the condition presents bilaterally. For patients with early vision 
loss, non-optical aids can be helpful. Some of these include a flashlight for night 
mobility and a mobility cane. Optically, reverse telescopes to enhance the 
peripheral field can be helpful in addition to magnification devices for central 
vision loss.  In the past, for patients with end-stage RP (i.e.,  light perception or 
worse), an Argus II Retinal Prosthesis implant was considered.2 This implant sent 
a signal downstream of the affected retina in the visual pathway, restoring some 
movement detection and resolution of shapes. (This device is limitedly available.) 
Regardless of the stage of vision loss and treatment, patients with RP will benefit 
from management through a coordinated team effort. 
 
In this manuscript we describe the clinical and molecular findings in a patient with 
a unilateral and progressive form of retinal degeneration. We will also discuss a 
potential diagnosis of unilateral RP based on clinical history and genetic findings. 
Although our patient did not exhibit bilateral loss, a brief explanation of how low 





  A 68-year-old Hispanic female was referred to the low vision rehabilitation clinic 
due to progressive vision loss of her left eye (OS) that began 15 years prior. She 
had no visual complaints regarding her right eye (OD). She reported that her OS 
had fundus findings compatible with RP in her early 40’s.  
 
Her medical history included hypercholesterolemia, type 2 diabetes mellitus 
diagnosed 6 months ago (uncertain if controlled at initial presentation), and hearing 
loss in the right ear diagnosed when she was 3 years old (presumably associated 
40





with maternal rubella). She denied any history of trauma, retinal detachment, 
infectious or inflammatory disease. She had no known allergies. Medications 
included ibuprofen 600 mg, aspirin 81 mg, atorvastatin 20 mg, lisinopril 5 mg, 
omeprazole 20 mg, and captopril 25 mg.  She was not on diabetic medications. She 
was a former occasional smoker but denied alcohol consumption or recreational 
drug use. Her family history included a paternal uncle with vision loss of unknown 
etiology. 
 
At presentation, her best-corrected visual acuities were 20/20 OD and 20/40 OS. 
Contrast sensitivity testing showed slight reduction in OD (log 1.50) and severe 
reduction OS (log 0.75). Pupil testing revealed a 3 to 4+ relative afferent pupillary 
defect OS. A 120-point screening automated Humphrey visual field demonstrated 
115/120 points seen OD and 0/120 points seen OS with a size III white 
stimulus(Figure A.1a).  
 
Figure A.1a. 120 point visual field showing an essentially full field OD, and near-total visual field 
loss OS. The HVF 30-2 shows some central vision sparring OS. 
 
Fundus evaluation revealed senescent macular changes and atypical scattered 
granular white dots throughout the midperiphery in both eyes (Figures A.2, OD and 
A.3 for OS). In the OD, extensive drusenoid deposits were present in the macula 
and posterior pole consistent with intermediate stage nonexudative age-related 
macular degeneration (Figure A.2).  
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   Figure A.2. Fundus photo OD showing drusen throughout the macula and posterior pole.  
 
   
  Figure A.3. Two fundus photos of OS showing patchy areas of RPE atrophy, bone-spicule shaped    
  RPE hyperplasia, arteriolar attenuation, choroidal vessel sclerosis, optic atrophy, and mild macular  
  drusen. 
 
 
The optic nerve head appeared normal with a 0.3 cup-to-disc ratio and the retinal 
vasculature was unremarkable aside from a mildly enlarged arteriolar light reflex. 
Minor pigmentary changes were present OD, and only a single locus of retinal 
pigment epithelium (RPE) hyperplasia was present along a retinal vessel in the 
nasal midperiphery. Fundus autofluorescence (FAF) imaging OD revealed pinpoint 
scattered speckled or granular mixed hypofluorescent and hyperfluorescent 
changes throughout the posterior pole (Figure A.4).   
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Figure A.4. FAF imaging showing scattered pinpoint speckles of mixed hypofluorescent and 
hyperfluorescent changes and a ring of hypofluorescence surrounding the optic nerve head OD. FAF 
imaging OS shows patchy and geographic-shaped areas of hypoflourescence that are confluent 
surrounding the optic nerve, as well as mild relative hyperflourescence in the remaining macular 
region. 
 
Few large-sized drusen in the macular region corresponded to rings of 
hyperfluorescence with central hypofluorescence. Additionally, a ring of 
hypofluorescence surrounding the optic nerve head was present consistent with 
nonpathologic peripapillary atrophy. Structural optical coherence tomography 
(OCT) OD confirmed the presence of large-sized soft drusenoid deposits within the 
macular region. OCT angiography OD demonstrated normal appearing inner retinal 
vasculature, however, mild focal perfusion deficits were present within the 
choriocapillaris underlying areas of drusen (Figure A.5). No signs of exudative age-
related macular degeneration (such as fluid or choroidal neovascularization) were 




Figure A.5. OCT angiography demonstrating decreased choriocapillaris and retinal perfusion OS. 
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Ophthalmoscopy OS revealed mild drusenoid deposits within the macula and 
scattered throughout the posterior pole, however, drusenoid changes were far less 
extensive OS compared to OD (Figure A.3). Patchy areas of RPE atrophy and 
classic appearing bone-spicule shaped RPE hyperplasia were present throughout 
the posterior pole and periphery OS. The retinal vasculature demonstrated severe 
diffuse arteriolar attenuation and moderate attenuation of the retinal veins. The 
large chorodial vessels had a whitened appearance consistent with vascular 
sclerosis. Severe and diffuse pallor of the neuroretinal rim tissue without cupping 
was present OS. The cup-to-disc ratio was measured as 0.4. FAF imaging OS 
revealed patchy and mostly geographic-shaped areas of hypoflourescence that were 
confluent surrounding the optic nerve (Figure A.4). Additionally, mild relative 
hyperflourescence appeared to be present in the remaining macular and foveal 
regions. OCT angiography OS revealed decreased perfusion in both the retinal and 
choriocapillaris circulatory systems (Figure A.5). Near total choriocapillaris 
dropout was present underlying circular geographic areas of RPE loss within the 
superior macula (Figure A.5).  Structural OCT imaging OS demonstrated outer 
retinal and RPE atrophy with loss of the ellipsoid zone, or photoreceptor integrity 
line, throughout the macula that spared the foveal region. Few hyperreflective hard 
drusenoid-type subretinal deposits were present (Figure A.6).  Optic nerve head and 
nerve fiber layer (NFL) OCT imaging showed probable inferior and superior NFL 
loss OS as well as a relative decrease in NFL thickness OS as compared to OD 
(Figure A.7).  
 
 
        Figure A.6. Structural macular OCT imaging OS demonstrating outer retinal and RPE atrophy  
        with loss of the ellipsoid zone throughout the macula that spares the center of the fovea. 
 
44






         Figure A.7. Optic nerve head and NFL OCT showing probable inferior and superior NFL loss  
         OS as well as a relative decrease in average NFL thickness OS as compared to OD. 
 
A series of electrodiagnostic tests were performed to evaluate retinal function. A 
Diopsys® full-field ERG was obtained utilizing a red flash on a blue background. 
This waveform appeared normal OD, however, the response OS was nearly 
extinguished with reduced A-wave, B-wave and photoptic negative response 
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Figure A. 8. Diopsys® full-field ERG obtained utilizing a red flash on a blue background showing 
normal response OD and near extinguished response OS. 
 
Similarly, Diagnosys® dark-adapted full-field flash ERGs revealed normal A and 
B-waves OD, and a severely reduced response OS (Figure A.9). Focusing on more 
localized areas of reduction, the multifocal ERG demonstrated mild reduction in 
the OD and severe reduction in the OS responses. A contrast sensitivity ERG 
(which detects functional performance of retinal ganglion cells) showed normal 
response OD and reduced response OS. 
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Figure A.9. Diagnosys® light-adapted flicker ERG (left) and dark-adapted full-field flash ERG 
(right). Dark-adapted full-field flash ERG shows normal A and B-waves OD, and near extinguished 
response OS. 
 
Additional information including bloodwork and carotid ultrasound imaging was 
ordered to rule out any attributable infectious, inflammatory, autoimmune, or toxic 
retinal disease process. The following test results were within normal limits 
(summarized on Table B.1): complete blood count (CBC), comprehensive 
metabolic panel, erythrocyte sedimentation rate (ESR), rapid plasma reagin (RPR), 
fluorescent treponemal antibody absorption (FTA-ABS), Lyme antibody, 
toxoplasma antibody, and lupus panel. However, C-reactive protein (CRP) was 
elevated at 20.0 mg/L, outside the normal range of < 8 mg/L, and glucose and blood 
urea nitrogen (BUN) to creatinine ratio were also flagged as high. Blood glucose 
was 116 mg/dL, outside the normal range of 65-99 mg/dL, consistent with her 
history of type 2 diabetes. Because she had hypercholesteremia, we attributed the 
elevated CRP to be an inflammatory marker for associated cardiovascular disease.  
Her most current carotid ultrasound revealed patent carotid and vertebral arteries 
bilaterally. 
 
Components Results Components Results 
Carotid/vertebral 
arteries 
WNL ESR WNL 
RPR WNL FTA-ABS WNL 
Lyme Ab WNL Lupus panel WNL 
Toxoplasma Ab WNL CRP High: 20.0 mg/L,  
CBC WNL Glucose High: 116 mg/dL 
Comp metabolic panel WNL BUN/creatine High 
Table B.1. Laboratory studies showing within normal levels (WNL) values for all components 
except C-Reactive Protein (CRP), glucose, and BUN/creatine ratio. 
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To further assist in the diagnosis, the patient underwent genetic testing via a 
research program sponsored by the Foundation Fighting Blindness. Sequence 
analysis using the Blueprint Genetics (BpG) Retinal Dystrophy Panel Plus 
identified heterozygous missense mutations in AGBL5 [c.14466G>A, p. 
(Arg489His)] and TULP1 [c.38C>A, p. (Ala13Asp)] genes. These genetic changes 
were classified as Variants of Uncertain Significance (VUS) because they are 
inherited with an autosomal recessive pattern and thus, in heterozygosity, were not 
consistent with a diagnosis of bilateral RP. The patient was educated on RP and 
counseled on the genetic findings.  
 
While URP did not necessitate low vision rehabilitation, the co-morbidity of 
AMD with advanced peripheral field loss OS did.  So, management with low vision 
rehabilitation was implemented. Recommendations included a yellow filter to 
subjectively enhance contrast sensitivity binocularly as both eyes had minimal 
reduction in contrast sensitivity,  and good, direct illumination on her tasks to 
enhance contrast.  To address the near total field loss on her left side, we provided 
training on scanning her environment to the left and wearing single vision distance 
spectacles.  It was recommended that she perform a behind the wheel driving 
evaluation with the Department of Motor Vehicles as well. This was suggested as 
a protective measure for the patient as the state driving law has a recommended, 




URP is a rare disease that usually presents more commonly in adults.14,15 It has 
later onset than bilateral RP and a definitive diagnosis requires thorough 
investigation including confirmation of normal ERG tests and exclusion of 
asymmetrical RP as well as other infectious, inflammatory, traumatic, toxic, and 
vascular retinal conditions.14,19 For this patient the clinical presentation, 
progression of vision loss, and the results of anciliary tests were consistent with 
URP and fit most of the criteria for URP diagnosis proposed by Francois and 
Verriest.11,15 These criteria include: (i) unilateral ocular RP presentation, (ii) normal 
fundus appearance and electroretinogram (ERG) findings in the fellow eye, (iii) 
exclusion of infectious etiology, and (iv) sufficiently long period of observation 
(more than 5 years). In our patient, fundus findings consistent with RP were present 
in the OS, with only a single locus of RPE hyperplasia present along a retinal vessel 
in the nasal midperiphery in the OD. ERG testing was normal OD and laboratory 
testing ruled out an attributable infectious disease. Additionally, our patient was 
diagnosed with RP in the OS approximately 25 years prior to her examinations at 
our clinic.  
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There are characteristic fundus features and anciliary test findings that aid with 
the diagnosis of RP. In our patient, fundoscopy revealed the pigmentary bone 
spicules, arteriolar attenuation, and disc pallor in the OS which directed us to a 
diagnosis of RP. The bilateral drusen was worse OD, and is indicative of coexisting 
nonexudative age-related macular degeneration. Otherwise, the fundus appearance 
OD lacked the distinctive signs of RP. ERG provided a quantitative objective 
measurement of retinal function,2,20 with photopic and scotopic ERG results 
severely reduced in the affected eye and normal in the fellow eye, as expected in 
an individual with URP.  
 
Fundus autofluorescence imaging reflects retinal metabolism as well as the 
amount and distribution of lipofuscin.21 Therefore, hypofluorescence is suggestive 
of disruption or loss of the photoreceptors and/or RPE, while hyperfluorescence is 
suggestive of retinal stress and impending degeneration. It often reveals even subtle 
RPE damage that may be difficult to detect with funduscopic examination alone. 
Fundus autofluorescence imaging in our patient helped highlight widespread and 
large areas of RPE atrophy that spared the foveal region OS and supported our 
presumed diagnosis of RP. Her OS also exhibited mild hyperfluorescence within 
the remaining macular/foveal region which is a well-described FAF feature in eyes 
with RP.22 In contrast, FAF imaging OD lacked characteristic features of RP such 
as midperipheral hypofluorescence and macular hyperfluorescence. The diffuse 
stippled hyper/hypofluorescence pattern present in the posterior pole OD is likely 
atrributable to nonexudative age-related macular degeneration.  
 
Optical coherence tomography demonstrated outer retinal and RPE atrophy with 
relative foveal sparing OS only, which is consistent with URP. The intact foveal 
ellipsoid zone OS is consistent with the relatively good visual acuity. Asymmetric 
decreased choriocapillaris perfusion, more severe in the OS, was visualized by OCT 
angiography imaging and is likely attributable to age-related macular degeneration 
in her OD alone and the combination of advanced RP and age-related macular 
degeneration in her OS. Additionally, the retinal perfusion was also drastically 
reduced OS (compared to OD) which is consistent with URP, since research 
suggests that both reduced retinal and choriocapillaris perfusion are manifestations 
of RP.23 
 
The patient experienced moderate hearing impairment in one ear with an intact 
vestibular system diagnosed early in life. Her symptoms did not correlate with 
Usher syndrome or other types of syndromic RP.  (Usher syndrome is classified 
into three subtypes including USH type I, type II, and type III.24,25 Type I is the 
most severe, presenting with profound to total deafness, vestibular dysfunction, and 
progressive RP at birth. Type II is as common, but not as severe as type I, presenting 
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with variable degree of hearing impairment, intact vestibular system, and RP onset 
at puberty. Type III presents with moderate deafness, inconsistent vestibular 
dysfunction, and RP symptoms.)  The patient’s mother was infected with rubella 
during pregnancy, and there is ample evidence indicating that maternal rubella can 
lead to hearing loss and retinopathy either bilaterally or unilaterally.26 However, the 
patient had congenital hearing loss of the right ear while retinopathy was diagnosed 
only during her fifth decade of life in the contralateral eye.  Given this, maternal 
rubella could explain her congenital hearing loss but it is unlikely related to her 
retinal disease.  
 
Pseudo-RP due to infection, autoimmunity, trauma,  or drug toxicity were ruled 
out with laboratory testing. The patient showed augmented CRP levels, which may 
be related to her hypercholesterolemia or uncontrolled diabetic condition (glucose 
level of 116 mg/dL; normal range of 65-99 mg/dL). However, an inflammatory 
pseudo-RP could not be completely ruled out in this patient and would require 
further investigation. 
 
The association between AGBL5 and retinitis pigmentosa 75 was proposed in 
2015 and new genetic variants have been discovered since then.27,28  AGBL5 
encodes ATP/GTP binding protein like 5 involved in the process of 
deglutamylation.29 TULP1 gene is involved in photoreceptor function and the 
lifespan of photoreceptor cells.30  Bilateral RP can be caused by homozygous or 
compound heterozygous mutations in the autosomal genes AGBL5 and 
TULP1.27,29,31 In this case, genetic testing found missense mutations in only one of 
the two alleles of these RP-associated genes (heterozygous expression). Whether 
or not these changes were causing RP in this case remains elusive. Three 
possibilities could explain the pathogenic expression of these gene variants: (I) low 
level mosaicism, defined by the presence of at least two cell populations with 
different genotypes in her retina, (II) the second mutation could have occurred in 
her retina as a somatic event, or (III) the wild type allele could have been silenced 
via epigenetic changes. The patient was negative to known X-linked RP pathogenic 
variants, which suggested a somatic mutation, mosaicism, or gene silencing as 
possible etiologies. This was in agreement with previous reports of unilateral 
RP.16,19,32 In order to better assess the distribution and potential role of her genetic 
variants in RP, we recommended extending genetic testing to any family member 
affected by retinal disease.  
 
A recent study involving over two thousand patients with inherited retinal 
dystrophy found that a molecular diagnosis can be achieved via genetic testing in 
approximately 70% of patients.33 This leaves up to 30% of all retinal dystrophy 
cases without a definitive molecular diagnosis. Thus, although genetic testing is 
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informative, further research is needed to obtain the scientific and clinical 
knowledge to determine the role of novel mutations, like the ones identified in our 
patient. In this regard, the possibility of a novel AGBL5 and TULP1digenic form of 
RP cannot be ruled out completely. However, the unilateral presentation in our 
patient suggested a retina-specific event (e.g., somatic or epigenetic change) as a 
likely second hit. Again, to the best of our knowledge, this is the first report of a 
patient with probable URP expressing these two genetic variants in 
heterozygosity.  Genetic tests for Inherited Retinal Diseases (IRD), like the one 
used for our patient, use blood or saliva samples to find genetic changes present in 
germline cells. Somatic mutations, low level mosaicism, or epigenetic changes fail 
to be detected on these tests. Of note, these have been proposed as mechanisms 
driving URP. To find the underlying molecular mechanism that would provide a 
definitive diagnosis for the patient, a biopsy of the retinal tissues would be needed.  
 
Based on the clinical findings, her case history, and our quantitative data 
combined with her genetic finding of recessive variants expressed in 
heterozygosity, we propose either low level mosaicism or a somatic event involving 
her OS as a plausible explanation. Her genetic and clinical information has been 
included in the My Retina Tracker database and is now available to clinicians and 
researchers. Building a community of clinical scientists will enable us to better 
correlate genotypes and clinical manifestations in inherited retinal disease and to 
improve patient care. 
 
Other clinical tests performed were useful for understanding and addressing the 
functional needs of our patient. It is our goal as low vision rehabilitation clinicians 
to enable our patients to function in their environment, maintain independence, and 
optimize the quality of their lives. Generally, most patients with only one severely 
impacted eye do not require low vision services. However, our patient, despite 
having a functionally normal OD, had both contrast loss OU and peripheral field 
loss OS that affected her bilateral visual function and for which management of 
these complaints was within the scope of low vision services. She also had the 
coexistence of early age-related macular degeneration in the macula of the OD 
more than the OS. Therefore, we felt it was also relevant to educate her on available 
resources should there be an eventual progression of macular degeneration.  
 
Contrast sensitivity testing is an alternate method of quantifying the visual 
function of an individual. Often contrast sensitivity testing can detect a reduction 
in visual function earlier than visual acuity loss and can explain visual complaints 
that are disproportionate to acuity loss alone. In this case, our patient was 
experiencing severe contrast sensitivity reduction OS and mild to moderate contrast 
sensitivity loss OD. We feel this was due to the comorbidity of her macular 
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degeneration with RP.  Enhancement of contrast sensitivity with yellow filters is a 
known treatment option and, in this case, provided our patient with some subjective 
improvement in her vision.34 In addition, the contrast enhancement feature of 
electronic video magnifiers and digital media, good lighting, and glare filters can 
be helpful for both URP and age-related macular degeneration.35-37 
 
The 120 point screening visual field and 30-2 threshold visual fields were used to 
assess the patient’s overall functional visual field, both in extent and sensitivity.  A 
reverse telescope is ordinarily useful to enhance bilateral constriction of visual 
field; however this was not indicated or useful for our patient due to her better 
functioning OD. Orientation and mobility training can also be recommended for 
those with bilaterally reduced peripheral field loss. This training is ideally 
implemented prior to symptomatic vision loss to better prepare them for significant 
functional vision loss.37-39 For our patient, incorporating scanning techniques to her 
left side to compensate for the reduced left field was encouraged.  
 
There are other functional consdierations for patients with RP and macular 
degeneration.  Driving rehabilitation may assist our patients to drive more 
comfortably and safely. Every region has its own regulations regarding driving 
requirements and recommendations. For those who no longer meet the 
requirements for driving in their jurisdiction, low vision rehabilitation can address 
alternate transportation options.40 For school aged children, they may receive 
supervision from Teachers of the Visually Impaired (TVI) and be provided with 
Individualized Education Programs (IEP).41,42 For those seeking employment, or 
currently employed, vocational training or rehabilitative services can be an 
option.35,40,41 For the elderly, independent living skills can assist them to better 
adapt to their home with the remaining vision.36 With reduced vision, individuals 
are more at risk to develop depression, so it is important to provide counseling 
services and encourage support from family members.36,43 A visual impairment can 
alter quality of life, but it should not prevent anyone from experiencing an 
independent fulfilling life. 
 
  CONCLUSION 
 
  Unilateral RP is a rare presentation of RP. When such a case presents itself, the 
clinician must thoroughly evaluate possible mimicries of RP. The literature on URP 
is scarce, thus more research is needed to fully understand this condition. It is 
important to evaluate the patient’s visual function as a whole, and to consider 
education and rehabiliation resources when appropriate to improve visual function. 
This case demonstrated that while the complications from her RP OS presented 
with peripheral vision issues, when combined with bilateral macular degeneration, 
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functional impairment occurred.  Early intervention with low vision education was 
recommended and will aid the patient if vision continues to change from her 
comorbidities.  
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